Introduction
============

Interleukin-17 (IL-17) is a relatively newly described family of pro-inflammatory cytokines that consists of six family members (IL-17A--F).[@b1-ott-11-703] IL-17 is produced by CD4^+^ memory T cells, and it is involved in both innate and adaptive immune responses.[@b2-ott-11-703],[@b3-ott-11-703] It has been reported that IL-17A, a pro-inflammatory cytokine, is associated with the pathogenesis of chronic inflammatory diseases, autoimmune diseases,[@b4-ott-11-703],[@b5-ott-11-703] and cancer progression.[@b6-ott-11-703],[@b7-ott-11-703]

There are many studies that focus on the relationship between IL-17A G197A polymorphism and gastric cancer.[@b8-ott-11-703]--[@b23-ott-11-703] These studies are all based on experimental results, but their results are always inconsistent. Since 2015, only one meta-analysis has been conducted, and 11 case-control studies were included in this meta-analysis.[@b24-ott-11-703] Today, more than five studies that assessed the association between IL-17A G197A polymorphism and the risk of gastric cancer have been published. Therefore, we performed an updated meta-analysis to further determine an accurate relationship between IL-17A G197A polymorphism and gastric cancer susceptibility.

Materials and methods
=====================

Publication search
------------------

We conducted a publication search in PubMed, Excerpta Medica Database, and CNKI databases (up to June 10, 2017) using the following search strategy: "interleukin-17A or interleukin 17A or IL-17A or IL17A", "polymorphism", and "gastric cancer". No language restrictions were applied. Studies had to meet the following criteria: 1) case-control studies; 2) diagnoses of all patients with malignant tumors were confirmed by pathological or histological examination; 3) the study assessed the association between gastric cancer risk and the IL-17A G197A polymorphism. The following exclusion criteria were used: 1) unpublished studies or abstracts; 2) duplicate publications; and 3) insufficient data were reported.

Data extraction
---------------

For each study, the following characteristics were extracted: first author, year of publication, ethnicity, sample size (total cases and controls), source of controls, genotype distributions in cases and controls, and *P*-value of Hardy--Weinberg equilibrium (HWE).[@b25-ott-11-703] Disagreements were resolved by discussion.

Statistical analysis
--------------------

Odds ratios (ORs) with corresponding 95% CIs were calculated to clarify the strength of the association between IL-17A G197A polymorphism and gastric cancer risk. Five genetic models were assessed: homozygote model (AA vs GG), heterozygote model (GA vs GG), recessive model (AA vs GA+GG), dominant model (AA+GA vs GG), and allele model (A vs G). Subgroup analyses were conducted according to ethnicity and source of controls.

Heterogeneity was calculated by using both *χ*^2^-based *Q*-statistic and *I*^2^-statistic.[@b26-ott-11-703] If *P*≥0.1 and *I*^2^\<50%, the fixed-effects model (Mantel--Haenszel method) was chosen.[@b27-ott-11-703] Otherwise, the random effects model (Der Simonian--Laird method) was used.[@b28-ott-11-703] Moreover, sensitivity analysis was performed to assess the stability of the results. Publication bias was assessed with funnel plots and Egger's test.[@b29-ott-11-703] All of the statistical tests were carried out with STATA version 12.0 (Stata corporation, College Station, TX, USA). *P*\<0.05 was considered significant, and all *P*-values were two sided.

Results
=======

Characteristics of eligible studies
-----------------------------------

A flow diagram illustrating the study selection process is shown in [Figure 1](#f1-ott-11-703){ref-type="fig"}. Through literature search and selection, a total of 16 publications[@b8-ott-11-703]--[@b23-ott-11-703] including 6,624 cases and 7,631 controls were included in the meta-analysis. [Table 1](#t1-ott-11-703){ref-type="table"} shows the main characteristics of the included studies.

Meta-analysis
-------------

Overall, the IL-17A G197A polymorphism was associated with an increased gastric cancer risk in all genetic models (A vs G: OR =1.24, 95% CI =1.14--1.36, [Figure 2](#f2-ott-11-703){ref-type="fig"}; AA vs GG: OR =1.63, 95% CI =1.35--1.96, [Figure 3](#f3-ott-11-703){ref-type="fig"}; GA vs GG: OR =1.12, 95% CI =1.01--1.25, [Figure 4](#f4-ott-11-703){ref-type="fig"}; AA+GA vs GG: OR =1.23, 95% CI =1.11--1.35, [Figure 5](#f5-ott-11-703){ref-type="fig"}; AA vs GA+GG: OR =1.54, 95% CI =1.27--1.87, [Figure 6](#f6-ott-11-703){ref-type="fig"}). The HWE of each study was taken into consideration. After eliminating studies whose distribution of genotype in controls deviated from HWE, the outcome remained statistically significant. These results are shown in [Table 2](#t2-ott-11-703){ref-type="table"}.

When subgroup analysis was carried out based on ethnicity, significant associations were found in all five genetic models in Asian population (A vs G: OR =1.25, 95% CI =1.15--1.37; AA vs GG: OR =1.62, 95% CI =1.33--1.97; GA vs GG: OR =1.16, 95% CI =1.07--1.25; AA+GA vs GG: OR =1.24, 95% CI =1.15--1.33; AA vs GA+GG: OR =1.51, 95% CI =1.23--1.85), and statistically significant associations were found in the following genetic model in Caucasian population (AA vs GA+GG: OR =2.19, 95% CI =1.40--3.44).

When results were stratified by source of controls, IL-17A G197A polymorphism was associated with a significantly increased gastric cancer risk in the hospital-based controls' subgroup (A vs G: OR =1.30, 95% CI =1.17--1.45; AA vs GG: OR =1.81, 95% CI =1.46--2.25; AA+GA vs GG: OR =1.27, 95% CI =1.12--1.43; AA vs GA+GG: OR =1.71, 95% CI =1.34--2.18). However, no associations were observed in population-based controls' subgroup in all five comparison models. All comparisons are listed in [Table 2](#t2-ott-11-703){ref-type="table"}.

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analyses showed that omitting an individual study from all the analyses did not affect the pooled ORs significantly and no substantial change was detected, indicating that the overall results of the present study are stable ([Figure 7](#f7-ott-11-703){ref-type="fig"}).

Begg's funnel plot was used to assess the publication bias of included literature. The shapes of the funnel plots did not show any evidence of obvious asymmetry, indicating the absence of publication bias ([Figure 8](#f8-ott-11-703){ref-type="fig"}).

Discussion
==========

Genetic and environmental factors, life style, and *Helicobacter pylori* infections have been considered as playing essential roles in the development of gastric cancer,[@b30-ott-11-703],[@b31-ott-11-703] but the precise etiology of the disease remains inconsistent.

IL-17 is a critical inflammatory cytokine that plays an important role in chronic inflammation, autoimmune diseases, and cancer.[@b32-ott-11-703] The IL-17A G197A is located in the 5′ region near the *IL-17A* gene, and it may regulate the gene transcription.[@b33-ott-11-703] A previous study has conflicting results about the association between IL-17A G197A polymorphism and gastric cancer risk, which may be because of relatively small sample size and different genetic background.[@b8-ott-11-703] Meta-analysis is a powerful method to evaluate gene--disease associations, by collecting all available published studies to obtain more precise results.[@b34-ott-11-703]

With the development of molecular epidemiology, numerous studies explored the effects of IL-17A G197A polymorphism on gastric cancer susceptibility. In 2014, Yu et al[@b35-ott-11-703] carried out a meta-analysis and revealed that the IL-17A G197A polymorphism was associated with a significantly increased gastric cancer risk. In their work, they identified only six case-control studies evaluating the association between the IL-17A G197A polymorphism and gastric cancer risk. In 2015, Li et al[@b24-ott-11-703] conducted a meta-analysis to assess the association between IL-17A G197A polymorphism and gastric cancer susceptibility with 11 case-control studies and revealed that IL-17A G197A polymorphism was associated with gastric cancer risk. Therefore, we collected all available published literature and performed an updated meta-analysis of 16 independent case-control studies containing 6,624 cases and 7,631 controls. In the meta-analysis, significant associations between IL-17A G197A polymorphism and gastric cancer risk were observed in all five genetic models. The HWE of each study was taken into consideration. After eliminating studies whose distribution of genotype in controls deviated from HWE, the outcome remained statistically significant. Similar associations were also observed in Asian population (A vs G: OR =1.25, 95% CI =1.15--1.37; AA vs GG: OR =1.62, 95% CI =1.33--1.97; GA vs GG: OR =1.16, 95% CI =1.07--1.25; AA+GA vs GG: OR =1.24, 95% CI =1.15--1.33; AA vs GA+GG: OR =1.51, 95% CI =1.23--1.85), in Caucasian population (AA vs GA+GG: OR =2.19, 95% CI =1.40--3.44), and in the hospital-based controls' subgroup (A vs G: OR =1.30, 95% CI =1.17--1.45; AA vs GG: OR =1.81, 95% CI =1.46--2.25; AA+GA vs GG: OR =1.27, 95% CI =1.12--1.43; AA vs GA+GG: OR =1.71, 95% CI =1.34--2.18).

Several limitations need to be addressed. First, due to heterogeneity, the results of our meta-analysis should be interpreted. Second, the overall outcomes were based on unadjusted ORs. Lacking the information on detailed individual data limited our more precise analysis on adjusted estimates by other factors like age and sex. This limitation may cause serious confounding bias. Third, meta-analysis is a type of retrospective study, and recall and selection bias may be present.

In conclusion, our meta-analysis revealed that IL-17A G197A polymorphism may increase gastric cancer risk. However, larger studies are still required to assess the interaction of IL-17A G197A polymorphism with gastric cancer risk.
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![Forest plot of the association between IL-17A G197A polymorphism and gastric cancer risk in the allele model (A vs G) among the overall populations.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** IL, interleukin; OR, odds ratio.](ott-11-703Fig2){#f2-ott-11-703}

![Forest plot of the association between IL-17A G197A polymorphism and gastric cancer risk in the homozygote model (AA vs GG) among the overall populations.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** IL, interleukin; OR, odds ratio.](ott-11-703Fig3){#f3-ott-11-703}

![Forest plot of the association between IL-17A G197A polymorphism and gastric cancer risk in the heterozygote model (GA vs GG) among the overall populations.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** IL, interleukin; OR, odds ratio.](ott-11-703Fig4){#f4-ott-11-703}

![Forest plot of the association between IL-17A G197A polymorphism and gastric cancer risk in the dominant model (AA+GA vs GG) among the overall populations.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** IL, interleukin; OR, odds ratio.](ott-11-703Fig5){#f5-ott-11-703}

![Forest plot of the association between IL-17A G197A polymorphism and gastric cancer risk in the recessive model (AA vs GA+GG) among the overall populations.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** IL, interleukin; OR, odds ratio.](ott-11-703Fig6){#f6-ott-11-703}

![Sensitivity analysis about IL-17A G197A polymorphism and gastric cancer risk in the dominant model (AA+GA vs GG).](ott-11-703Fig7){#f7-ott-11-703}

![Begg's funnel plots to examine publication bias between IL-17A G197A polymorphism and gastric cancer risk in the dominant model (AA+GA vs GG).\
**Notes:** Plots are shown with pseudo 95% confidence limits. Each point represents a separate study for the indicated association.\
**Abbreviations:** SE, standard error; OR, Odds ratio.](ott-11-703Fig8){#f8-ott-11-703}

###### 

Characteristics of studies included in the meta-analysis

  Author                                       Year   Ethnicity   Source of controls   Cases   Controls   Case   Control   HWE                     
  -------------------------------------------- ------ ----------- -------------------- ------- ---------- ------ --------- ----- ----- ----- ----- ---------
  Shibata et al[@b8-ott-11-703]                2009   Asian       Hospital-based       287     523        94     124       69    175   299   49    \<0.001
  Chen[@b17-ott-11-703]                        2010   Asian       Population-based     1,042   1,090      300    522       220   325   541   224   0.967
  Wu et al[@b9-ott-11-703]                     2010   Asian       Population-based     945     768        210    485       250   193   371   204   0.351
  Arisawa et al[@b10-ott-11-703]               2012   Asian       Hospital-based       333     583        112    137       84    218   293   72    0.08
  Rafiei et al[@b11-ott-11-703]                2013   Caucasian   Population-based     161     171        56     61        44    78    72    21    0.491
  Qinghai et al[@b12-ott-11-703]               2014   Asian       Hospital-based       293     550        126    122       45    273   216   61    0.069
  Kutikhin et al[@b13-ott-11-703]              2014   Caucasian   Population-based     60      300        24     26        10    99    165   36    0.009
  Gonzalez-Hormazabal et al[@b14-ott-11-703]   2014   Mixed       Hospital-based       147     172        103    36        8     105   59    8     0.937
  Wang et al[@b15-ott-11-703]                  2014   Asian       Hospital-based       462     462        160    211       91    214   190   58    0.124
  Zhang et al[@b16-ott-11-703]                 2014   Asian       Population-based     260     512        110    102       48    258   187   67    \<0.001
  Wu et al[@b18-ott-11-703]                    2014   Asian       Hospital-based       945     768        210    485       250   193   371   204   0.351
  Gao et al[@b19-ott-11-703]                   2015   Asian       Hospital-based       572     573        239    250       83    260   241   72    0.17
  Hou and Yang[@b20-ott-11-703]                2015   Asian       Hospital-based       326     326        121    149       56    161   136   29    0.001
  Qi et al[@b21-ott-11-703]                    2015   Asian       Hospital-based       252     252        100    110       42    122   105   25    0.73
  Yang et al[@b22-ott-11-703]                  2016   Asian       Hospital-based       386     374        200    128       58    203   123   48    \<0.001
  Zhao et al[@b23-ott-11-703]                  2016   Asian       Hospital-based       153     207        51     76        26    95    94    18    0.437

**Abbreviation:** HWE, Hardy--Weinberg equilibrium.

###### 

Meta-analysis of the IL-17A polymorphism and gastric cancer risk

  Groups and subgroups     Comparison   Test of association   Test of heterogeneity                   
  ------------------------ ------------ --------------------- ----------------------- ------- ------- ------
  Total studies            A vs G       1.24                  1.14--1.36              0.000   0.000   67.0
  AA vs GG                 1.63         1.35--1.96            0.000                   0.000   66.9    
  GA vs GG                 1.12         1.01--1.25            0.030                   0.040   41.9    
  AA+GA vs GG              1.23         1.11--1.35            0.000                   0.027   44.8    
  AA vs GA+GG              1.54         1.27--1.87            0.000                   0.000   76.3    
  HWE (yes)                A vs G       1.23                  1.10--1.37              0.000   0.000   71.4
  AA vs GG                 1.56         1.26--1.94            0.000                   0.000   68.4    
  GA vs GG                 1.15         1.05--1.25            0.002                   0.160   30.0    
  AA+GA vs GG              1.23         1.10--1.38            0.000                   0.050   45.3    
  AA vs GA+GG              1.44         1.16--1.78            0.001                   0.000   75.0    
  **Ethnicity**                                                                                       
  Asian                    A vs G       1.25                  1.15--1.37              0.000   0.001   65.0
  AA vs GG                 1.62         1.33--1.97            0.000                   0.000   69.8    
  GA vs GG                 1.16         1.07--1.25            0.000                   0.160   28.3    
  AA+GA vs GG              1.24         1.15--1.33            0.000                   0.169   27.4    
  AA vs GA+GG              1.51         1.23--1.85            0.000                   0.000   79.0    
  Caucasian                A vs G       1.30                  0.73--2.32              0.377   0.023   80.7
  AA vs GG                 1.91         0.77--4.75            0.166                   0.078   67.9    
  GA vs GG                 0.94         0.64--1.37            0.743                   0.133   55.8    
  AA+GA vs GG              1.10         0.53--2.31            0.797                   0.040   76.3    
  AA vs GA+GG              2.19         1.40--3.44            0.001                   0.213   35.4    
  **Source of controls**                                                                              
  Hospital-based           A vs G       1.30                  1.17--1.45              0.000   0.001   63.8
  AA vs GG                 1.81         1.46--2.25            0.000                   0.002   62.7    
  GA vs GG                 1.13         0.99--1.29            0.067                   0.031   48.1    
  AA+GA vs GG              1.27         1.12--1.43            0.000                   0.040   46.1    
  AA vs GA+GG              1.71         1.34--2.18            0.000                   0.000   75.2    
  Population-based         A vs G       1.08                  0.99--1.17              0.078   0.184   37.9
  AA vs GG                 1.16         0.99--1.37            0.073                   0.341   10.4    
  GA vs GG                 1.10         0.97--1.26            0.147                   0.215   32.8    
  AA+GA vs GG              1.12         0.99--1.28            0.070                   0.205   34.6    
  AA vs GA+GG              1.07         0.93--1.23            0.317                   0.272   23.1    

**Abbreviations:** IL, interleukin; OR, odds ratio; HWE, Hardy--Weinberg equilibrium.
